Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2015 Jan 22;24(4):677–682. doi: 10.1158/1055-9965.EPI-14-1224

Table 3.

Screening and prostate cancer (PC) mortality outcomes in the projected population (N=10,000) when PCA3 varies by grade, for select strategies from Table 2. Grade-specific sensitivities refer to the PCA3 test properties alone. Grade is either low grade (LG) or moderate to high-grade (M-HG).

Strategy LG Median PCA3 M-HG Median PCA3 LG Sensitivity of PCA3 M-HG Sensitivity of PCA3 LG Cases Detected M-HG Cases Detected Over-diagnoses PC Deaths Lives Saved
PSA(4)+PCA3(20) 50 50 0.758 0.758 531 389 291 223 130
30 85 0.630 0.850 443 437 272 223 130
20 103 0.500 0.874 353 449 241 228 125
PSA(4)+ PCA3(35) 50 50 0.616 0.616 431 316 237 247 105
30 85 0.445 0.752 312 386 211 246 107
20 103 0.297 0.790 211 406 178 250 103